secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021648
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth
--------------------------------------------------------------------------------

- Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).
- Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.
- Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.
- Full-year 2024 outlook reiterated: net sales growth of at least 16%.
- Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/0001628280-24-021648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828024021648/cdxc-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer